

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following best describes 5-year results of the Phase III ECHELON-2 trial evaluating brentuximab vedotin versus chemotherapy for patients with CD30-positive peripheral T-cell lymphoma (PTCL)?
 - a. Significantly improved PFS
 - b. Significantly improved OS
 - c. Both a and b**
 - d. Neither a nor b
2. Which of the following any-grade adverse events was most commonly reported in patients receiving brentuximab vedotin for PTCL in the Phase III ECHELON-2 study?
 - a. Headache
 - b. Insomnia
 - c. Peripheral sensory neuropathy**
 - d. Rash
3. CD30 positivity is highest among which of the following subtypes of PTCL?
 - a. Angioimmunoblastic T-cell lymphoma
 - b. Mycosis fungoides
 - c. Anaplastic large cell lymphoma**
 - d. CD30-positivity is equal in the above subtypes
4. Which of the following best describes outcomes from the Phase II VALENTINE-PTCL01 trial investigating valemestostat monotherapy for relapsed or refractory PTCL?
 - a. Responses were observed only in angioimmunoblastic T-cell lymphoma
 - b. Responses were observed in anaplastic large cell lymphoma
 - c. Responses were observed only in angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma
 - d. Responses were observed across all peripheral T-cell lymphoma subtypes**
5. What was the approximate overall response rate observed with duvelisib in patients with relapsed/refractory PTCL in the updated expansion phase analysis of the Phase II PRIMO trial?
 - a. 11%
 - b. 23.5%
 - c. 48.5%**
 - d. >70%